Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Denali Buyout Validates F-star’s Asset-Centric Model

Executive Summary

Denali Therapeutics will pay around $470m in upfront and milestone payments to acquire its CNS bispecific antibody development partner F-star Gamma, lending credence to F-star’s business model of individual, asset-specific spin offs.    

You may also be interested in...



Deal Watch: Takeda Continues Shire Merger Prep With Out-License Of Relugolix Rights

As it narrows focus to core therapeutic areas ahead of acquiring Shire, Takeda sends uterine fibroid and endometriosis rights to compatriot firm ASKA. Zai Lab and Crescendo team up on antibody candidate for inflammatory indications.

F-star Option Deal With Merck On Bispecific IO Antibodies

'Asset-centric' bispecific antibody developer F-star has agreed an option deal for a package of immuno-oncology-focused antibodies with Merck of Germany.

Denali Deal & F-star’s Innovative Asset Centric Business Model

Jane Dancer, chief business officer at F-star – a Cambridge, UK-based biotech – chats to Mike Ward, global director of content for Informa Pharma Intelligence, on the sidelines of the recent BIO-Europe partnering conference in Cologne, Germany.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC123171

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel